WHO Globocan Fact Sheet 2008 for the Philippines [http://globocan.iarc.fr/Pages/fact_sheets_population.aspx]
Domingo EJ, Dy Echo AVV. Epidemiology, prevention and treatment of cervical cancer in the Philippines. J Gynecol Oncol. 2009;20(1):11–6.
Article
PubMed
PubMed Central
Google Scholar
Domingo EJ, Noviani R, Noor MRM, Ngelangel CA, Limpaphayom KK, Van Thuan T, et al. Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam. Vaccine. 2008;26:M71–9.
Society PC. Philippine Cancer Facts and Estimates 2010. Manila: Philippine Cancer Society Manila Cancer Registry and the Department of Health Rizal Cancer Registry; 2010.
Google Scholar
WHO/ICO. Human Papillomavirus and Related Cancers Summary Report 2010 for the Philippines. Barcelona, Spain: WHO/ICO Information Centre on HPV and Cervical Cancer; 2010.
Google Scholar
DOH Philippines. Administrative Order no. 3-B s. 1997: Department of Health Guidelines on papanicolaou smear procedure. Manila: DOH Philippines; 1997.
University of the Philippines-Department of Health Cervical Cancer Screening Study Group. Delineation of an appropriate and replicable cervical cancer screening program for Filipino women. Manila: University of the Philippines-Department of Health Cervical Cancer Screening Study Group; 2001.
DOH Philippines. Administrative order no. 2005–2006: Establishment of a cervical cancer screening program. Manila: DOH Philippines; 2005.
Cancer WHOIAfRo. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 90. Lyon, France: World Health Organization; 2007.
Google Scholar
de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56.
Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst. 1999;91(6):506–11.
Article
CAS
PubMed
Google Scholar
Ngelangel C, Muñoz N, Bosch FX, Festin MR, Deacon J, Jacobs MV, et al. Causes of cervical cancer in the Philippines: a case–control study. J Natl Cancer Inst. 1998;90(1):43–9.
Quek SC, Lim BK, Domingo E, Soon R, Park J-S, Vu TN, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia across 5 countries in Asia. Int J Gynecol Cancer. 2013;23(1):148–56.
Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30:F123–38.
Article
CAS
PubMed
PubMed Central
Google Scholar
World Health Organization. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec. 2009;84(15):118–31.
International Health Policy Program HITAP. The Progress Report: Research for Development of an Optimal Policy Strategy for Prevention and Control of Cervical Cancer in Thailand. Bangkok, Thailand: Population and Reproductive Health Capacity Building Program, The World Bank; 2007.
Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A, Chichareon S, et al. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics. 2011;29(9):781–806.
Drummond MF. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005.
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMC Med. 2013;11(1):80.
Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine. 2010;28(11):2356–9.
Article
PubMed
Google Scholar
DOH Philippines. Formulary Executive Council Guidelines. Manila: DOH Philippines; 2013.
Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151(12):1158–71.
Article
CAS
PubMed
Google Scholar
WHO Global Health Observatory Data Repository 2011 for the Philippines [http://apps.who.int/gho/data/view.main.LT62150?lang=en]
Redaniel MT, Laudico A, Mirasol-Lumague MR, Gondos A, Uy GL, Toral JA, et al. Ethnicity and health care in cervical cancer survival: comparisons between a Filipino resident population, Filipino-Americans, and Caucasians. Cancer Epidemiol Biomark Prev. 2009;18(8):2228–34.
Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. Can Med Assoc J. 2007;177(5):469–79.
Article
Google Scholar
Philippine Statistics Authority-National Statistical Coordination Board. Summary of Projected Population, by Five-Year Interval, Philippines: 2000–2040. Manilas: Philippine Statistics Authority-National Statistical Coordination Board; 2013.
Sritipsukho P. The Systematic Review of the Operating Characteristics of Screening Tests Including VIA, PAP smear, and HPV DNA testing. Bangkok: International Health Policy Program, Health Intervention and Technology Assessment Program, Population and Reproductive Health Capacity Building Program, The World Bank; 2007.
Google Scholar
Tongsiri S. The Thai Population-based Preference Scores for EQ-5D health states. London: University of London; 2009.
Google Scholar
EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health policy (Amsterdam, Netherlands). 1990;16(3):199.
Article
Google Scholar
Chichareon S. Economic burden of life-time treatment cost, and quality of life among invasive cervical cancer patients treated at university hospitals and cancer centers in Thailand. In: The Thai Gynecologic Oncology Collaborative Group, editor. Clinical Research Collaboration Network. 2008.
Google Scholar
Philippine Statistics Authority - National Statistics Coordination Board. Consumer Price Index for All Income Households in the Philippines by Major Commodity Group. Manila: Philippine Statistics Authority - National Statistics Coordination Board; 2013.
Average exchange rate Philippine peso per US dollar 2013 [http://www.x-rates.com/average/?from=USD&to=USD&amount=1&year=2013]
DOH Philippines. HPV Vaccine - Dossier for Inclusion in the Philippine National Formulary. Manila: DOH Philippines; 2013.
DOH Philippines. Implementation costs of the Expanded Program on Immunization. Manila: DOH Philippines; 2013.
Philippine Health Insurance Corporation. Database on claims for cervical procedures and standard Philhealth-Z benefit case-rates for cervical cancer 2011–2012. Manila: Philippine Health Insurance Corporation; 2013.
Society of Gynecologic Oncologists of the Philippines. Clinical practice guidelines for the management of cervical cancer. Manila: Society of Gynecologic Oncologists of the Philippines; 2012.
DOH Philippines. Drug Price Reference Index database 2012. Manila: DOH Philippines; 2012.
Group TTGOC. Tumour Registry Database: Cervical Cancer. Bangkok, Thailand; 2007.
Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17(5):479–500.
Article
CAS
PubMed
Google Scholar
Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied methods of cost-effectiveness analysis in healthcare. Oxford: Oxford University Press; 2010.
Pa S. The Systematic Review of the Operating Characteristics of Screening Tests Including VIA, PAP Smear, and HPV DNA testing. Bangkok, Thailand: International Health Policy Program, Health Intervention and Technology Assessment Program, Population and Reproductive Health Capacity Building Program, The World Bank; 2007.
Google Scholar
Ngelangel C, Limson G, Cordero C, Abelardo A, Avila J, Festin M, et al. Acetic-acid guided visual inspection vs. cytology-based screening for cervical cancer in the Philippines. Int J Gynecol Obstet. 2003;83(2):141–50.
Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2005;353(20):2158–68.
Haug C. The risks and benefits of HPV vaccination. JAMA. 2009;302(7):795–6.
Article
PubMed
Google Scholar
McCredie MRSK, Paul C, Baranyai J, Medley G, Jones RW, Skegg DC. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncology. 2008;9(5):425–34.
Article
PubMed
Google Scholar
Tomljenovic L, Pierre Spinosa J, A Shaw C. Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies:(how) effective and safe? Curr Pharm Des. 2013;19(8):1466–87.
CAS
PubMed
Google Scholar
Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Human Vaccines & Immunotherapeutics. 2012;8(3):390–7.
World Health Organization. Background paper for SAGE discussions: Evidence Based Recommendations on Human papilloma Virus (HPV) Vaccines Schedules. Geneva, Switzerland: World Health Organization; 2014.
Malagón T, Drolet M, Boily M-C, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781–9.
Gerhardus A, Razum O. A long story made too short: surrogate variables and the communication of HPV vaccine trial results. J Epidemiol Community Health. 2010;64(5):377–8.
Article
PubMed
Google Scholar
Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369(9574):1693–702.